OptiLight is the first intense pulsed light (IPL) device to be approved by the United States Food and Drug Administration and listed by the Therapeutic Goods Administration in Australia for the management of dry eye disease due to meibomian gland dysfunction (MGD).
Three patented features only available with OptiLight include:
- Optimal pulse technology (OPT), which delivers optimal energy with no-spike consistency, offering reproducible results and treatment consistency,
- Multiple sequential pulsing, which provides a balance between light energy delivery and cooling periods to enhance treatment comfort, efficacy, and safety, while allowing for more energy to be delivered safely to the target area, and
- The OPT handpiece, which enables operators to get as close to the lash line as possible for greater treatment outcomes.
Contact: Lumenis (AUS) 1800 586 364 or (NZ) 0800 239 015
